



For Immediate Release – April 13, 2010

CERES NANOSCIENCES COMPLETES USADA FUNDED CLINICAL STUDY TO MEASURE HGH IN URINE AND ESTABLISH INITIAL HUMAN BASELINE LEVELS

MANASSAS, Va.--- Ceres Nanosciences LLLP has completed a study to measure baseline levels of Human Growth Hormone (HGH) present in the urine of non-doping healthy adults. The trial was funded by the United States Anti Doping Agency (USADA).

The trial collected urine samples from a population of adult patients and used the Ceres Nanotrap® technology to consistently measure HGH concentrations present in order to establish a reference range of natural HGH concentrations in the urine of non-doping adults (the baseline).

The trial utilized the Ceres-patented Nanotrap®, an innovative technology that captures protein particles in body fluids and protects them from degradation when they are extracted for analysis. Ceres Nanosciences continues to collect data on HGH levels in urine and has recently expanded its capability to conduct a larger clinical trial to continue investigation of the analytical challenges in measuring urinary HGH. Ceres is seeking additional industry funding for development of this test.

"In our view, the results of our scientific study demonstrate the ability to measure HGH in urine using existing FDA approved assays coupled to Nanotrap enrichment" said Lance Liotta, M.D., Ph. D., co-director of the Center for Applied Proteomics and Molecular Medicine at George Mason University, "We now are exploring the feasibility of measuring specific isoforms of HGH in urine using the Nanotrap technology, which has not been done before" he continued. "We plan to proceed methodically through this process with the highest degree of scientific rigor and peer-review".

MORE

About Ceres Nanosciences, LLLP

Ceres Nanosciences, LLLP is a privately held company focused on the development of research reagents and diagnostic products using its unique and proprietary Nanotrap™ capture particle technology. Ceres' business goals are to develop a number of commercial applications of the Nanotrap® for high-demand diagnostics and other needs in the life science industry.

Contact:

Ross M. Dunlap

Ceres Nanosciences, LLLP

1.800.615.0418 ext. 202

rdunlap@ceresnano.com